LEO Pharma is an independent, innovation-based pharmaceutical company founded in 1908 and headquartered in Ballerup. From our earliest history, LEO Pharma has gone beyond conventional approaches to serve patients and meet their needs.

We focus on therapies for the treatment of skin diseases, such as psoriasis, Chronic Hand Eczema (CHE), atopic dermatitis, acne and infections - conditions that cause serious physical and social discomfort, serving more than 95 million patients around the world every year.

LEO Pharma invests heavily in R&D and 13% of our turnover is allocated to research and development of new innovative solutions. 

Our research and development organization is situated at our headquarters outside Copenhagen in Denmark. The organization is divided into two distinct areas: Research and Early Development and Development to release the full potential of our early-stage and late-stage pipeline activities.

We drive our research and development projects in multi-disciplinary and cross-functional project teams integrating advanced knowledge in R&D disciplines with expertise in clinical practices and therapeutic needs.